Population
In vitro assays and in vivo antithrombotic models
Design
Preclinical
Authors
Loading...
Supports progression of razaxaban to human trials; leaves open translation of preclinical efficacy to clinical outcomes.
Razaxaban was discovered as a highly potent, selective, and orally bioavailable factor Xa inhibitor suitable for clinical development.
Quan et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: